Financial Insights’s BioMarin Pharmaceuticals BMRN Stock Holding History

Financial Insights’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,556	Closed	-$249K	–	154
2023 Q1	$249K	Sell	2,556 -2,267	-47%	-$235K	0.1%	149
2022 Q4	$499K	Buy	4,823 +2,076	+76%	+$195K	0.24%	81
2022 Q3	$233K	Buy	+2,747	New	+$245K	0.16%	107

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Financial Insights's BMRN Position: Q2 2023 in Review

Financial Insights sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 2,556 shares — an estimated $249K sold.

Financial Insights first reported a position in BMRN in Q3 2022 and held it in 3 quarters. The position peaked at $499K in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Financial Insights reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Financial Insights sold 2,556 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $249K.
Financial Insights first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 3 quarters.
Financial Insights's BioMarin Pharmaceuticals position peaked at $499K in Q4 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Financial Insights's 13F filing for Q2 2023, filed 25 Jan 2024.